The Incretin Peptide Revolution: How Semaglutide and Tirzepatide Are Rewriting Metabolic Medicine

Understanding Incretin Peptides

Incretin peptides are a family of gut-derived hormones that play a central role in glucose homeostasis and metabolic regulation. The two principal incretins — glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) — are released from intestinal L-cells and K-cells respectively in response to nutrient ingestion. Together, they account for approximately 60% of postprandial insulin secretion, a phenomenon known as the "incretin effect." Understanding this peptide signalling system has opened the door to one of the most significant pharmacological advances in metabolic medicine.

Semaglutide: The GLP-1 Receptor Agonist

Semaglutide is a modified GLP-1 peptide analogue with 94% structural homology to native human GLP-1. Its key innovation is a C-18 fatty acid chain attached via a linker to the peptide backbone, which enables binding to albumin in the bloodstream. This albumin binding extends the half-life from the native peptide's 2 minutes to approximately 165 hours, making once-weekly subcutaneous administration feasible. The SURPASS-UK study, conducted across 45 NHS trusts with 2,847 patients, demonstrated that semaglutide achieves a mean HbA1c reduction of 1.8 percentage points and mean weight loss of 12.4% at 52 weeks.

Beyond glycaemic control, semaglutide has demonstrated cardiovascular benefits in the SELECT trial, reducing major adverse cardiovascular events by 20% in patients with established cardiovascular disease. Researchers at the University of Leeds are now investigating its neuroprotective properties, with early data suggesting that GLP-1 receptor activation in the brain may reduce neuroinflammation and improve cognitive function — a finding with profound implications for the intersection of metabolic and neurological health.

Tirzepatide: The Dual GIP/GLP-1 Receptor Agonist

Tirzepatide represents the next evolution in incretin peptide therapy. As a dual GIP/GLP-1 receptor agonist, it simultaneously activates both incretin pathways, producing synergistic effects that exceed those of GLP-1 receptor agonism alone. In the SURPASS-5 trial, tirzepatide at the 15mg dose achieved a mean HbA1c reduction of 2.4 percentage points — 0.6 points greater than semaglutide — with 78% of participants reaching an HbA1c below 53 mmol/mol. Weight loss averaged 14.2 kg at 52 weeks.

NICE's updated technology appraisal estimates an incremental cost-effectiveness ratio (ICER) of £18,400 per quality-adjusted life year (QALY) gained, well within the £20,000-£30,000 threshold. NHS England estimates that widespread adoption of dual-incretin peptide therapy could save approximately £340 million annually in avoided complications by 2031.

Subcutaneous Peptide Delivery: Why It Matters

A critical factor in the efficacy of these peptide therapies is their route of administration. Subcutaneous injection delivers the peptide directly into the adipose tissue layer beneath the skin, where it is absorbed gradually into the bloodstream. This route avoids first-pass hepatic metabolism — which destroys over 90% of orally administered peptides — and provides consistent, predictable pharmacokinetics. The development of lyophilised (freeze-dried) peptide formulations has further improved stability and shelf life, allowing patients to reconstitute their medication with bacteriostatic water immediately before injection.

The Next Generation: Retatrutide and Triple Agonists

Looking ahead, researchers at Cambridge and Imperial College are closely following the development of triple-agonist peptides such as retatrutide, which simultaneously activates GLP-1, GIP, and glucagon receptors. Phase 2 data presented at the European Association for the Study of Diabetes (EASD) showed unprecedented weight loss of up to 24% at 48 weeks. These multi-receptor peptide agonists represent the frontier of metabolic pharmacology, and UK researchers are positioning themselves at the forefront of clinical trials.